Similarly, research conducted by Fujimoto et al. has demonstrated that in pancreatic cancer, downregulation of RUNX3 expression and its subsequent methylation serve as negative prognostic indicators, especially when combined with CA19-9 levels, enhancing the sensitivity for detecting early-stage pancreatic cancer [119]. Here, RUNX3 is linked to pancreatic neoplasm.